Type 1 Diabetes Market Report and Forecast 2024-2032

Type 1 Diabetes Market Outlook

The type 1 diabetes market size was valued at USD 7.9 billion in 2023, driven by the increasing prevalence of diabetes across the 7 major markets. The market size is anticipated to grow at a CAGR of 6.8% during the forecast period of 2024-2032 to achieve a value of USD 15.3 billion by 2032.

Type 1 Diabetes: Introduction

Type 1 diabetes is a medical condition that arises from insufficient insulin production by the pancreas in the human body. Insulin is a crucial hormone that supports the entry of sugar (glucose) into cells, enabling the generation of energy. In the absence of adequate insulin, glucose accumulates in the bloodstream. Formerly recognized as juvenile diabetes or insulin-dependent diabetes, type 1 diabetes is not limited to a specific age group and can manifest in individuals of all ages. Recognizable symptoms of type 1 diabetes include frequent urination, persistent thirst, continuous hunger, unexplained weight loss, alterations in vision, and persistent fatigue.

Type 1 Diabetes Market Analysis

The market for diabetes treatment is rapidly growing, and companies are seeking opportunities to create innovative solutions that will lead to better patient outcomes. The treatment landscape for type 1 diabetes has recently undergone significant developments that are expected to have a major impact on the market.

The FDA's approval of Lantidra, a new therapy derived from deceased donor pancreatic cells, marks a major advancement in the field. This allogeneic pancreatic islet cellular therapy is designed to help individuals with type 1 diabetes who are struggling to maintain healthy blood sugar levels despite intensive management efforts. The use of deceased donor cells in this innovative approach represents a paradigm shift in diabetes therapeutics.

In addition, the recent financial sponsorship of Amsterdam-based start-up, Advanced Microbiome Interventions, with a 300,000 Euro (USD 3,28,398) convertible loan from Innovatiefonds Noord-Holland, highlights the growing interest and investment in developing treatments for type 1 diabetes. This financial support is expected to propel AMI's research efforts, potentially leading to novel therapeutic interventions. These actions and shifting interests toward the treatment of type 1 diabetes are expected to bolster the type 1 diabetes market growth.

Furthermore, Sanofi's strategic acquisition of Provention Bio, Inc. for approximately USD 2.9 billion is poised to reshape the landscape of type 1 diabetes treatments. This move strengthens Sanofi's core asset portfolio with TZIELD (teplizumab-mzwv), a first-in-class therapy that has been proven to delay the onset of Stage 3 type 1 diabetes. The acquisition aligns with Sanofi's strategic focus on differentiated products and represents a significant step towards intercepting and preventing immune-mediated diseases, including type 1 diabetes. These transformative developments indicate a promising era of innovation and investment in the type 1 diabetes market, which is expected to lead to improved outcomes for individuals managing this chronic condition and boost market growth.

Type 1 Diabetes Market Segmentations

Market Breakup by Insulin Analog

• Rapid-Acting Insulin

• Short-Acting Insulin

• Long-Acting Insulin

Market Breakup by Mode of Product Type

• Injections/IV

• Inhaled insulin

Market Breakup by Route of Administration

• Parenteral (Subcutaneous, Intravenous)

• Oral

Market Breakup by End User

• Hospital

• Research Institutes

• Home Care

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Type 1 Diabetes Market Overview

The market is expected to witness significant growth in the forecast period, propelled by technological advancements in remote blood glucose monitoring devices. These innovations are expected to enhance the management of Type 1 diabetes, providing patients with more accessible and efficient means of monitoring their blood glucose levels. The market is also driven by strategic initiatives such as acquisitions, partnerships, and collaborations among key industry players. These efforts aim to foster innovation, improve treatment options, expand the reach of diabetes management solutions, and further boost the type 1 diabetes market growth.

Geographically, the United States has been leading the market, boasting the largest revenue share. The prevalence of Type 1 diabetes, particularly among children and adolescents, has contributed to this dominance. The active involvement of major industry players in research and development activities further fuels market growth in North America.

Type 1 Diabetes Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Eli Lilly

• Pfizer

• Stryker Corporation

• Abbott Laboratories

• DiaVasc, Inc.

• Biodel, Inc.

• Sanofi

• Merck

• Astellas Pharma

• Mankind Corporation

• Biodel, Inc,

• Macrogenics

• DiaVacs, Inc.

• Novo Nordisk

• Braun Melsungen

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report